CD19 Monoclonal Antibody (SJ25C1), Super Bright™ 436, eBioscience™, Invitrogen™

Description

• Description: The SJ25C1 monoclonal antibody reacts with human CD19, a 95 kDa transmembrane glycoprotein
• CD19 is expressed by B cells during all stages of development excluding the terminally differentiated plasma cells
• Follicular dendritic cells also express this molecule
• CD19, along with CD21, CD81, Leu13, and MHC class II, form a multimolecular complex that associates with the BCR
• Signaling through CD19 induces tyrosine phosphorylation, calcium flux, and proliferation of B cells
• The SJ25C1 antibody and the HIB19 monoclonal antibody recognize overlapping epitopes
• Applications Reported: This SJ25C1 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This SJ25C1 antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells
• This can be used at 5 μL (0.125 μg) per test
• A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL
• Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test
• It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest
• Super Bright 436 can be excited with the violet laser line (405 nm) and emits at 436 nm
• We recommend using a 450/50 bandpass filter, or equivalent
• Please make sure that your instrument is capable of detecting this fluorochrome
• CD19 is a member of the immunoglobulin superfamily and has two Ig like domains
• The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lambda light chains
• CD19 appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage
• Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen
• The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation, and is expressed in all B cell precursor leukemias
• Lymphocytes proliferate and differentiate in response to various concentrations of different antigens
• The ability of the B cell to respond in a specific, yet sensitive manner to the various antigens is achieved with the use of low-affinity antigen receptors
• CD19 is a cell surface molecule which assembles with the antigen receptor of B lymphocytes in order to decrease the threshold for antigen receptor-dependent stimulation
• Besides being a signal-amplifying coreceptor for the B cell receptor (BCR), CD19 can also signal independently of BCR co-ligation and is a central regulatory component upon which multiple signaling pathways converge
• Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.